The IV fluid industry is one of the most key players in the pharmaceutical industry in India. Every month, millions of IV fluid bags are used in hospitals, ranging from Tier-1 metros to Tier-3 District towns \u2014 both Normal Saline and Ringer’s Lactate, Dextrose and other specialty parenteral solutions. However, navigating this space, which is marked with a high demand for entrepreneurs and investors, is fraught with regulatory complexity, capital-intensive plants, and process engineering decisions which impact patient safety in direct ways. Hence the importance of the IV fluid (BFS technology) industry consultants in India. Its role is to either explore a greenfield LVP (Large Volume Parenteral) manufacturing plant or to add SVP (Small Volume Parenteral) lines to an existing pharmaceutical production facility, the right consultancy partner can be the difference between a viable, CDSCO-licensed production unit and a costly misstep.<\/p>\n
India is estimated to have a current IV fluid consumption of one billion bottles or bags per year \u2013 one of the biggest parenteral markets by volume in the world. The domestic market is growing at the rate of 7-9% annually, and is valued at around \u20b94,500-5,000 crore annually. This growth trajectory is sustainable and not cyclic because of the structural demand drivers, such as PMJAY hospital admissions, National Health Mission (NHM) district hospital expansion and increasing chronic disease burden. In this context, the number and sophistication of Indian industrial consultants in the IV fluid and parenteral business have picked up even higher scale, mirroring the complexity faced by the entrepreneurs in setting up a sterile manufacturing facility which meets the requirements of WHO-GMP and CDSCO Schedule M and adopts Blow-Fill-Seal (BFS) technology.<\/p>\n